# MK3207 for Treatment of Acute Migraines (3207-005)

> **NCT00712725** · PHASE2 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 676 (actual)

## Conditions studied

- Migraine

## Interventions

- **DRUG:** MK3207- 2.5 mg
- **DRUG:** MK3207- 5 mg
- **DRUG:** MK3207- 10 mg
- **DRUG:** MK3207- 20 mg
- **DRUG:** MK3207- 50 mg
- **DRUG:** MK3207- 100 mg
- **DRUG:** Comparator: placebo (unspecified)

## Key facts

- **NCT ID:** NCT00712725
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-07
- **Primary completion:** 2009-01
- **Final completion:** 2009-01
- **Target enrollment:** 676 (ACTUAL)
- **Last updated:** 2015-02-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00712725

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00712725, "MK3207 for Treatment of Acute Migraines (3207-005)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00712725. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*